id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S16219 R67163 |
Ahlqvist (Population-Based), 2024 | Attention-deficit/hyperactivity disorder (ADHD) - ICD-10 (F90) or ICD-9 (314) - Median (IQR) follow-up of 13.4 (7.6-19.8) years | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes Paracetamol use: maternal ITW/questionnaires during pregnancy | 1.07 [1.05;1.10] | 12,834/185,909 133,552/2,294,888 | 146,386 | 185,909 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S16218 R67160 |
Ahlqvist (Sibling), 2024 | Attention-deficit/hyperactivity disorder (ADHD) - ICD-10 (F90) or ICD-9 (314) - Median (IQR) follow-up of 13.4 (7.6-19.8) years | during pregnancy (anytime or not specified) | population based cohort retrospective | sibling excluded | Adjustment: Yes Control group: Sibling Paracetamol use: maternal ITW/questionnaires during pregnancy |
0.98 [0.94;1.02] excluded (control group) |
8,526/- 87,679/- | 96,205 | - |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S16220 R67165 |
Chen, 2019 | Diagnoses of ADHD (ICD-9-CM code: 314) by board-certified psychiatrists on the basis of diagnostic interviews and clinical judgement - Age 0 - 15 years old (mean diagnosis 3.71) | during pregnancy (anytime or not specified) | nested case control | unexposed (general population or NOS) | Adjustment: Yes Paracetamol use: prescription or medical files | 1.20 [1.01;1.42] | 676/3,236 274/1,514 | 950 | 3,236 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S16253 R67195 |
Ystrom or Gustavson (Gustavson 2021 - Sibling), 2017 | Attention deficit hyperactivity disorder - ICD-10 code F90 - Between 0 and 18 years old (Exposed 1–7 days) | during pregnancy (anytime or not specified) | prospective cohort | sibling excluded | Adjustment: Yes Control group: Sibling Paracetamol use: maternal ITW/questionnaires during pregnancy |
0.87 [0.70;1.08] excluded (control group) |
-/6,490 -/12,080 | - | 6,490 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S16290 R67298 |
Ystrom or Gustavson (Ystrom - Population-Based), 2017 | Attention-deficit/hyperactivity (ADHD - diagnosis of hyperkinetic disorder (F90.0, F90.1, F90.8, or F90.9)) - At 3-15 years old. | during pregnancy (anytime or not specified) | prospective cohort | unexposed (general population or NOS) | Adjustment: Yes Paracetamol use: maternal ITW/questionnaires during pregnancy | 1.12 [1.02;1.24] | -/52,707 -/60,266 | - | 52,707 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S16275 R67240 |
Liew, 2014 | Hyperkinetic disorder diagnosis (ICD-10: F90.0-F90.9) - Mean age of children at the end of follow-up: 10.7 years (range, 8.2-13.4 years) | during pregnancy (anytime or not specified) | prospective cohort | unexposed (general population or NOS) | Adjustment: Yes Paracetamol use: maternal ITW/questionnaires during pregnancy | 1.37 [1.19;1.59] | 551/36,187 283/28,135 | 834 | 36,187 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 4 studies | 1.16 [1.05;1.29] | 148,170 | 278,039 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Population-Based; 2: Ystrom - Population-Based;
Asymetry test p-value = NaN (by Egger's regression)
not enought points
excluded 16253, 16218